Immix Biopharma, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US45258H1068

USD

5.56

0.72 (14.88%)

Dec 05

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Kronos Bio, Inc.

Alpha Teknova, Inc.

Ocuphire Pharma, Inc.

SCYNEXIS, Inc.

FibroGen, Inc.

Capricor Therapeutics, Inc.

Anebulo Pharmaceuticals, Inc.

Werewolf Therapeutics, Inc.

Immix Biopharma, Inc.

Annovis Bio, Inc.

Evelo Biosciences, Inc.

Why is Immix Biopharma, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Immix Biopharma, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Immix Biopharma, Inc.

120.63%

-0.19

90.18%

S&P 500

12.66%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-40.27%

EBIT to Interest (avg)

-20.50

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.65

Sales to Capital Employed (avg)

Tax Ratio

0.20%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.68%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.89

EV to EBIT

-2.31

EV to EBITDA

-2.32

EV to Capital Employed

-8.02

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-217.96%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at USD -11.17 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -227.7 %

-8What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -6.61 MM has Fallen at -50.46%

NET PROFIT(Q)

At USD -6.62 MM has Fallen at -50.75%

ROCE(HY)

Lowest at -162.04%

Here's what is working for Immix Biopharma, Inc.

Debt-Equity Ratio

Lowest at -227.7 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Immix Biopharma, Inc.

Pre-Tax Profit

At USD -6.61 MM has Fallen at -50.46%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -6.62 MM has Fallen at -50.75%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)